Additive beneficial effects of amlodipine and atorvastatin in reversing advanced cardiac hypertrophy in elderly spontaneously hypertensive rats

Clinical and Experimental Pharmacology and Physiology

Volumn 36, Issue 11, 2009, Pages 1110-1119

  Lu, Jing Chao ^a   Cui, Wei ^a   Zhang, Hai Lin ^a   Liu, Fan ^a   Han, Mei ^a   Liu, De Min ^a   Yin, Hong Ning ^a   Zhang, Kai ^a   Du, Jun ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Atorvastatin; Cardiac hypertrophy; Hypertension; Reactive oxygen species

Indexed keywords

AMLODIPINE; ATORVASTATIN; CHOLESTEROL; PROTEIN P22; PROTEIN P40; PROTEIN P47; RAC1 PROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; BLOOD PRESSURE MEASUREMENT; CHOLESTEROL BLOOD LEVEL; CONTROL GROUP; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIASTOLIC DYSFUNCTION; DRUG EFFECT; ECHOCARDIOGRAPHY; FIBROSING ALVEOLITIS; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE FILLING; HEART VENTRICLE HYPERTROPHY; MOLECULAR MECHANICS; MONOTHERAPY; MORNING DOSAGE; NONHUMAN; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; UPREGULATION;

AGING; AMLODIPINE; ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; CARDIOMEGALY; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FIBROSIS; HEART FAILURE, DIASTOLIC; HEMODYNAMICS; HEPTANOIC ACIDS; MYOCYTES, CARDIAC; NADPH OXIDASE; NATRIURETIC PEPTIDE, BRAIN; OXIDATIVE STRESS; PYRROLES; RANDOM ALLOCATION; RATS; RATS, INBRED SHR; REACTIVE OXYGEN SPECIES; SUPEROXIDE DISMUTASE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 70449486143     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2009.05198.x     Document Type: Article

References (45)

1. Wachtell K, Okin PM, Olsen MH et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: The LIFE Study. Circulation 2007 116 : 700 705.
2. Seddon M, Looi YH, Shah AM. Oxidative stress and redox signalling in cardiac hypertrophy and heart failure. Heart 2007 93 : 903 907.
3. Takimoto E, Kass DA. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension 2007 49 : 241 248.
4. Date MO, Morita T, Yamashita N et al. The antioxidant N-2-mercaptopropionyl glycine attenuates left ventricular hypertrophy in in vivo murine pressure-overload model. J. Am. Coll. Cardiol. 2002 39 : 907 912.
5. Umemoto S, Tanaka M, Kawahara S et al. Calcium antagonist reduces oxidative stress by upregulating Cu/Zn superoxide dismutase in stroke-prone spontaneously hypertensive rats. Hypertens. Res. 2004 27 : 877 885.
6. Hasegawa H, Takano H, Kohro T et al. Amelioration of hypertensive heart failure by amlodipine may occur via antioxidative effects. Hypertens. Res. 2006 29 : 719 729.
7. Simko F. Statins: A perspective for left ventricular hypertrophy treatment. Eur. J. Clin. Invest. 2007 37 : 681 691.
8. Mason RP, Kubant R, Heeba G et al. Synergistic effect of amlodipine and atorvastatin in reversing LDL-induced endothelial dysfunction. Pharm. Res. 2008 25 : 1798 1806.
9. McKeage K, Siddiqui MA. Amlodipine/atorvastatin fixed-dose combination: A review of its use in the prevention of cardiovascular disease and in the treatment of hypertension and dyslipidemia. Am. J. Cardiovasc. Drugs 2008 8 : 51 67.
10. Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 2003 361 : 1149 1158. (Pubitemid 36398384)
11. Mason RP. Scientific rationale for combination of a calcium channel antagonist and an HMG-CoA reductase inhibitor: A new approach to risk factor management. Drugs 2008 68 : 885 900.
12. Muders F, Elsner D. Animal models of chronic heart failure. Pharmacol. Res. 2000 41 : 605 612.
13. Yoshii T, Iwai M, Li Z et al. Regression of atherosclerosis by amlodipine via anti-inflammatory and anti-oxidative stress actions. Hypertens. Res. 2006 29 : 457 466.
14. Birnbaum Y, Ye Y, Lin Y et al. Augmentation of myocardial production of 15-epi-lipoxin-a4 by pioglitazone and atorvastatin in the rat. Circulation 2006 114 : 929 935.
15. Fontaine D, Otto A, Fontaine J, Berkenboom G. Prevention of nitrate tolerance by long-term treatment with statins. Cardiovasc. Drugs Ther. 2003 17 : 123 128.
16. Bunag RD. Validation in awake rats of a tail-cuff method for measuring systolic pressure. J. Appl. Physiol. 1973 34 : 279 282.
17. Slama M, Ahn J, Varagic J, Susic D, Frohlich ED. Long-term left ventricular echocardiographic follow-up of SHR and WKY rats: Effects of hypertension and age. Am. J. Physiol. Heart Circ. Physiol. 2004 286 : H181 5.
18. Slama M, Ahn J, Peltier M et al. Validation of echocardiographic and Doppler indexes of left ventricular relaxation in adult hypertensive and normotensive rats. Am. J. Physiol. Heart Circ. Physiol. 2005 289 : H1131 6.
19. Bendall JK, Cave AC, Heymes C, Gall N, Shah AM. Pivotal role of a gp91 (phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation 2002 105 : 293 296.
20. 1 receptor blocker, valsartan, on atherosclerosis. Hypertension 2004 44 : 7 58 63.
21. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976 72 : 248 254.
22. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 1979 95 : 351 358.
23. Matsui H, Shimosawa T, Uetake Y et al. Protective effect of potassium against the hypertensive cardiac dysfunction: Association with reactive oxygen species reduction. Hypertension 2006 48 : 225 231.
24. Liu B, Han M, Wen JK. Acetylbritannilactone inhibits neointimal hyperplasia after balloon injury of rat artery by suppressing nuclear factor-κB activation. J. Pharmacol. Exp. Ther. 2008 324 : 292 298.
25. Liu YP, Wen JK, Zheng B, Zhang DQ, Han M. Acetylbritannilactone suppresses lipopolysaccharide-induced vascular smooth muscle cell inflammatory response. Eur. J. Pharmacol. 2007 577 : 28 34.
26. Kashyap ML, Hynd BA, Robinson K. A rapid and simple method for measurement of total protein in very low density lipoproteins by the Lowry assay. J. Lipid Res. 1980 21 : 491 495.
27. Lee TM, Lin MS, Chou TF, Tsai CH, Chang NC. Effect of pravastatin on development of left ventricular hypertrophy in spontaneously hypertensive rats. Am. J. Physiol. Heart Circ. Physiol. 2005 289 : H220 7.
28. Loch D, Levick S, Hoey A, Brown L. Rosuvastatin attenuates hypertension-induced cardiovascular remodeling without affecting blood pressure in DOCA-salt hypertensive rats. J. Cardiovasc. Pharmacol. 2006 47 : 396 404.
29. Zhou MS, Jaimes EA, Raij L. Atorvastatin prevents end-organ injury in salt-sensitive hypertension: Role of eNOS and oxidant stress. Hypertension 2004 44 : 186 190.
30. Habibi J, Whaley-Connell A, Qazi MA et al. Rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, decreases cardiac oxidative stress and remodeling in Ren2 transgenic rats. Endocrinology 2007 148 : 2181 2188.
31. Xu Z, Okamoto H, Akino M, Onozuka H, Matsui Y, Tsutsui H. Pravastatin attenuates left ventricular remodeling and diastolic dysfunction in angiotensin II-induced hypertensive mice. J. Cardiovasc. Pharmacol. 2008 51 : 62 70.
32. Chen MS, Xu FP, Wang YZ et al. Statins initiated after hypertrophy inhibit oxidative stress and prevent heart failure in rats with aortic stenosis. J. Mol. Cell. Cardiol. 2004 37 : 889 896.
33. Ichihara S, Noda A, Nagata K et al. Pravastatin increases survival and suppresses an increase in myocardial matrix metalloproteinase activity in a rat model of heart failure. Cardiovasc. Res. 2006 69 : 726 735.
34. Ge CJ, Lu SZ, Chen YD, Wu XF, Hu SJ, Ji Y. Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia. Heart Vessels 2008 23 : 91 5.
35. Su SF, Hsiao CL, Chu CW, Lee BC, Lee TM. Effects of pravastatin on left ventricular mass in patients with hyperlipidemia and essential hypertension. Am. J. Cardiol. 2000 86 : 514 518.
36. Gupta S, Das B, Sen S. Cardiac hypertrophy: Mechanisms and therapeutic opportunities. Antioxid. Redox Signal. 2007 9 : 623 652.
37. Ito N, Ohishi M, Yamamoto K et al. Renin-angiotensin inhibition reverses advanced cardiac remodeling in aging spontaneously hypertensive rats. Am. J. Hypertens. 2007 20 : 792 799.
38. Alvarez MC, Caldiz C, Fantinelli JC et al. Is cardiac hypertrophy in spontaneously hypertensive rats the cause or the consequence of oxidative stress?. Hypertens. Res. 2008 31 : 1465 1476.
39. Sirker A, Zhang M, Murdoch C, Shah AM. Involvement of NADPH oxidases in cardiac remodelling and heart failure. Am. J. Nephrol. 2007 27 : 649 660.
40. Nakamura T, Yamamoto E, Kataoka K et al. Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan. Hypertension 2008 51 : 296 301.
41. Umeji K, Umemoto S, Itoh S et al. Comparative effects of pitavastatin and probucol on oxidative stress, Cu/Zn superoxide dismutase, PPAR-gamma, and aortic stiffness in hypercholesterolemia. Am. J. Physiol. Heart Circ. Physiol. 2006 291 : H2522 32.
42. Gao L, Wang W, Li YL et al. Simvastatin therapy normalizes sympathetic neural control in experimental heart failure, roles of angiotensin II type 1 receptors and NAD(P)H oxidase. Circulation 2005 112 : 1763 1770.
43. Wassmann S, Laufs U, Muller K et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol. 2002 22 : 300 305.
44. Kushiro T, Mizuno K, Nakaya N et al. Pravastatin for cardiovascular event primary prevention in patients with mild-to-moderate hypertension in the management of elevated cholesterol in the primary prevention group of adult Japanese (MEGA) Study. Hypertension 2009 53 : 135 141.
45. Perreault S, Dragomir A, Blais L, Berard A, Lalonde L, White M. Impact of adherence to statins on chronic heart failure in primary prevention. Br. J. Clin. Pharmacol. 2008 66 : 706 716.